111 related articles for article (PubMed ID: 22290075)
41. Search for novel leads for histamine H3-receptor antagonists: oxygen-containing derivatives.
Stark H; Hüls A; Ligneau X; Arrang JM; Schwartz JC; Schunack W
Pharmazie; 1997 Jul; 52(7):495-500. PubMed ID: 9266588
[TBL] [Abstract][Full Text] [Related]
42. Dibasic biphenyl H3 receptor antagonists: Steric tolerance for a lipophilic side chain.
Bordi F; Rivara S; Dallaturca E; Carmi C; Pala D; Lodola A; Vacondio F; Flammini L; Bertoni S; Ballabeni V; Barocelli E; Mor M
Eur J Med Chem; 2012 Feb; 48():214-30. PubMed ID: 22222138
[TBL] [Abstract][Full Text] [Related]
43. Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 3: 5-Substituted 3-phenyl-1,2,4-oxadiazoles as potent antagonists.
Gfesser GA; Zhang H; Dinges J; Fox GB; Pan JB; Esbenshade TA; Yao BB; Witte D; Miller TR; Kang CH; Krueger KM; Bennani YL; Hancock AA; Faghih R
Bioorg Med Chem Lett; 2004 Feb; 14(3):673-6. PubMed ID: 14741266
[TBL] [Abstract][Full Text] [Related]
44. A new class of diamine-based human histamine H3 receptor antagonists: 4-(aminoalkoxy)benzylamines.
Apodaca R; Dvorak CA; Xiao W; Barbier AJ; Boggs JD; Wilson SJ; Lovenberg TW; Carruthers NI
J Med Chem; 2003 Aug; 46(18):3938-44. PubMed ID: 12930154
[TBL] [Abstract][Full Text] [Related]
45. From an atypical wake-promoting agent to potent histamine-3 receptor inverse agonists.
Dunn D; Raddatz R; Ator MA; Bacon ER; Chatterjee S
Chem Biol Drug Des; 2013 Mar; 81(3):433-5. PubMed ID: 23205610
[TBL] [Abstract][Full Text] [Related]
46. Identification of the antiarrhythmic drugs amiodarone and lorcainide as potent H3 histamine receptor inverse agonists.
Del Tredici AL; Ma JN; Piu F; Burstein ES
J Pharmacol Exp Ther; 2014 Jan; 348(1):116-24. PubMed ID: 24204014
[TBL] [Abstract][Full Text] [Related]
47. Benzylpiperidine variations on histamine H3 receptor ligands for improved drug-likeness.
Wingen K; Schwed JS; Isensee K; Weizel L; Zivković A; Odadzic D; Stark H
Bioorg Med Chem Lett; 2014 May; 24(10):2236-9. PubMed ID: 24745967
[TBL] [Abstract][Full Text] [Related]
48. N-Alkenyl and cycloalkyl carbamates as dual acting histamine H3 and H4 receptor ligands.
Więcek M; Kottke T; Ligneau X; Schunack W; Seifert R; Stark H; Handzlik J; Kieć-Kononowicz K
Bioorg Med Chem; 2011 May; 19(9):2850-8. PubMed ID: 21498080
[TBL] [Abstract][Full Text] [Related]
49. Discovery of a series of potent arylthiadiazole H(3) antagonists.
Xiao D; Palani A; Sofolarides M; Huang Y; Aslanian R; Vaccaro H; Hong L; McKittrick B; West RE; Williams SM; Wu RL; Hwa J; Sondey C; Lachowicz J
Bioorg Med Chem Lett; 2011 Jan; 21(2):861-4. PubMed ID: 21186123
[TBL] [Abstract][Full Text] [Related]
50. Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists.
Nagase T; Mizutani T; Ishikawa S; Sekino E; Sasaki T; Fujimura T; Ito S; Mitobe Y; Miyamoto Y; Yoshimoto R; Tanaka T; Ishihara A; Takenaga N; Tokita S; Fukami T; Sato N
J Med Chem; 2008 Aug; 51(15):4780-9. PubMed ID: 18598020
[TBL] [Abstract][Full Text] [Related]
51. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists.
Hancock AA
Biochem Pharmacol; 2006 Apr; 71(8):1103-13. PubMed ID: 16513092
[TBL] [Abstract][Full Text] [Related]
52. Development of chiral N-alkylcarbamates as new leads for potent and selective H3-receptor antagonists: synthesis, capillary electrophoresis, and in vitro and oral in vivo activity.
Sasse A; Kiec-Kononowicz K; Stark H; Motyl M; Reidemeister S; Ganellin CR; Ligneau X; Schwartz JC; Schunack W
J Med Chem; 1999 Feb; 42(4):593-600. PubMed ID: 10052966
[TBL] [Abstract][Full Text] [Related]
53. Synthesis and evaluation of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues as histamine-3 receptor antagonists.
Becknell NC; Dandu RR; Lyons JA; Aimone LD; Raddatz R; Hudkins RL
Bioorg Med Chem Lett; 2012 Jan; 22(1):186-9. PubMed ID: 22153342
[TBL] [Abstract][Full Text] [Related]
54. Diamine-based human histamine H3 receptor antagonists: (4-aminobutyn-1-yl)benzylamines.
Dvorak CA; Apodaca R; Xiao W; Jablonowski JA; Bonaventure P; Dugovic C; Shelton J; Lord B; Miller K; Dvorak LK; Lovenberg TW; Carruthers NI
Eur J Med Chem; 2009 Oct; 44(10):4098-106. PubMed ID: 19524331
[TBL] [Abstract][Full Text] [Related]
55. Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activity.
Cowart M; Gfesser GA; Browman KE; Faghih R; Miller TR; Milicic I; Baranowski JL; Krueger KM; Witte DG; Molesky AL; Komater VA; Buckley MJ; Diaz GJ; Gagne GD; Zhou D; Deng X; Pan L; Roberts EM; Diehl MS; Wetter JM; Marsh KC; Fox GB; Brioni JD; Esbenshade TA; Hancock AA
Biochem Pharmacol; 2007 Apr; 73(8):1243-55. PubMed ID: 17371699
[TBL] [Abstract][Full Text] [Related]
56. Meta-substituted aryl(thio)ethers as potent partial agonists (or antagonists) for the histamine H3 receptor lacking a nitrogen atom in the side chain.
Pelloux-Léon N; Fkyerat A; Piripitsi A; Tertiuk W; Schunack W; Stark H; Garbarg M; Ligneau X; Arrang JM; Schwartz JC; Ganellin CR
J Med Chem; 2004 Jun; 47(12):3264-74. PubMed ID: 15163206
[TBL] [Abstract][Full Text] [Related]
57. In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists.
Hancock AA; Diehl MS; Faghih R; Bush EN; Krueger KM; Krishna G; Miller TR; Wilcox DM; Nguyen P; Pratt JK; Cowart MD; Esbenshade TA; Jacobson PB
Basic Clin Pharmacol Toxicol; 2004 Sep; 95(3):144-52. PubMed ID: 15447739
[TBL] [Abstract][Full Text] [Related]
58. Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist.
Barbier AJ; Berridge C; Dugovic C; Laposky AD; Wilson SJ; Boggs J; Aluisio L; Lord B; Mazur C; Pudiak CM; Langlois X; Xiao W; Apodaca R; Carruthers NI; Lovenberg TW
Br J Pharmacol; 2004 Nov; 143(5):649-61. PubMed ID: 15466448
[TBL] [Abstract][Full Text] [Related]
59. A new class of histamine H3 receptor antagonists derived from ligand based design.
Roche O; Rodríguez Sarmiento RM
Bioorg Med Chem Lett; 2007 Jul; 17(13):3670-5. PubMed ID: 17498953
[TBL] [Abstract][Full Text] [Related]
60. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.
Yates SL; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Tedford CE
J Pharmacol Exp Ther; 1999 May; 289(2):1151-9. PubMed ID: 10215699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
